RecruitingPhase 2NCT04072042

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Principal Investigator
Weibin Zhang
Shanghai Jiao Tong University School of Medicine
Intervention
Apatinib monotherapy(drug)
Enrollment
30 target
Eligibility
8-65 years · All sexes
Timeline
20192027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04072042 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma

← Back to all trials